A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Study Designed to Evaluate the Safety, Efficacy, Pharmacokinetic and Pharmacodynamic Profile of Bertilimumab in Patients With Active Moderate to Severe Ulcerative Colitis
Phase of Trial: Phase II
Latest Information Update: 09 Jan 2018
At a glance
- Drugs Bertilimumab (Primary)
- Indications Ulcerative colitis
- Focus Proof of concept; Therapeutic Use
- Sponsors Immune Pharmaceuticals Inc
- 05 Jan 2018 Planned End Date changed from 1 Apr 2017 to 1 Mar 2019.
- 05 Jan 2018 Planned primary completion date changed from 1 Apr 2017 to 1 Aug 2018.
- 04 Aug 2017 According to Immune Pharmaceuticals media release, company has enrolled patients at 5 sites in Israel and 1 site in Russia and expect to complete the study in the second quarter of 2018.